Cefadroxil monohydrate
Executive Summary
International Trade Commission grants Bristol-Myers Squibb temporary relief Jan. 10 following a recent federal circuit court determination that the company's disputed '657 patent is "likely to be sustained" ("The Pink Sheet" Dec. 18, T&G-4). The ITC issued a cease and desist order prohibiting domestic marketing of the antibiotic by Biocraft, Kalipharma and Purepac unless a bond is posted for 68% of the "entered value of the imported articles," ITC said in a notice published in the Jan. 18 Federal Register. The commission also gave a temporary limited exclusion order prohibiting foreign manufacturers from importing the product without posting bond for 68% of its value. The orders will remain effective until the ITC reaches its final determination, due March 15.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.